OUST vs. BBIO
OUST (Ouster, Inc.) and BBIO (BridgeBio Pharma, Inc.) are both stocks. OUST operates in Electronic Components (Technology), while BBIO operates in Biotechnology (Healthcare). Over the past 5 years, OUST returned -20.38%/yr vs 1.89%/yr for BBIO. At a 0.35 correlation, their price movements are largely independent.
Performance
OUST vs. BBIO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, OUST achieves a 88.91% return, which is significantly higher than BBIO's -11.92% return.
OUST
- 1D
- 3.02%
- 1M
- 62.22%
- YTD
- 88.91%
- 6M
- 60.25%
- 1Y
- 180.19%
- 3Y*
- 93.76%
- 5Y*
- -20.38%
- 10Y*
- —
BBIO
- 1D
- -0.35%
- 1M
- -0.03%
- YTD
- -11.92%
- 6M
- -9.25%
- 1Y
- 74.44%
- 3Y*
- 61.48%
- 5Y*
- 1.89%
- 10Y*
- —
OUST vs. BBIO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
OUST Ouster, Inc. | 88.91% | 77.09% | 59.32% | -11.12% | -83.40% | -61.48% | 39.18% |
BBIO BridgeBio Pharma, Inc. | -11.92% | 178.75% | -32.03% | 429.79% | -54.32% | -76.54% | 80.76% |
Correlation
The correlation between OUST and BBIO is 0.29, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.29 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.37 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.35 |
Correlation (All Time) Calculated using the full available price history since Oct 12, 2020 | 0.35 |
Fundamentals
OUST:
$2.53B
BBIO:
$13.12B
OUST:
-$0.94
BBIO:
-$3.76
OUST:
13.17
BBIO:
23.00
OUST:
$185.33M
BBIO:
$566.04M
OUST:
$90.79M
BBIO:
$538.20M
OUST:
-$50.85M
BBIO:
-$602.24M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
OUST vs. BBIO — Risk / Return Rank
OUST
BBIO
OUST vs. BBIO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Ouster, Inc. (OUST) and BridgeBio Pharma, Inc. (BBIO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| OUST | BBIO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.19 | ||
| Sortino ratioReturn per unit of downside risk | +0.20 | ||
| Omega ratioGain probability vs. loss probability | 1.29 | 1.30 | -0.02 |
| Calmar ratioReturn relative to maximum drawdown | 3.29 | 3.70 | -0.41 |
| Martin ratioReturn relative to average drawdown | 6.10 | 9.25 | -3.15 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| OUST | BBIO | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.80 | 1.60 | +0.19 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.21 | 0.02 | -0.23 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.15 | 0.16 | -0.31 |
Drawdowns
OUST vs. BBIO - Drawdown Comparison
The maximum OUST drawdown since its inception was -98.01%, which is greater than BBIO's maximum drawdown of -92.80%. Use the drawdown chart below to compare losses from any high point for OUST and BBIO.
Loading charts...
Drawdown Indicators
| OUST | BBIO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.01% | -92.80% | -5.21% |
Max Drawdown (1Y)Largest decline over 1 year | -55.15% | -20.25% | -34.90% |
Max Drawdown (3Y)Largest decline over 3 years | -64.00% | -49.08% | -14.92% |
Max Drawdown (5Y)Largest decline over 5 years | -97.57% | -91.89% | -5.68% |
Current DrawdownCurrent decline from peak | -74.84% | -15.69% | -59.15% |
Average DrawdownAverage peak-to-trough decline | -78.08% | -45.80% | -32.28% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 29.68% | 8.07% | +21.61% |
Volatility
OUST vs. BBIO - Volatility Comparison
Ouster, Inc. (OUST) has a higher volatility of 40.06% compared to BridgeBio Pharma, Inc. (BBIO) at 12.10%. This indicates that OUST's price experiences larger fluctuations and is considered to be riskier than BBIO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| OUST | BBIO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 40.06% | 12.10% | +27.96% |
Volatility (6M)Calculated over the trailing 6-month period | 67.84% | 34.41% | +33.43% |
Volatility (1Y)Calculated over the trailing 1-year period | 101.07% | 46.75% | +54.32% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 96.60% | 85.95% | +10.65% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 95.63% | 83.80% | +11.83% |
Dividends
OUST vs. BBIO - Dividend Comparison
Neither OUST nor BBIO has paid dividends to shareholders.
Financials
OUST vs. BBIO - Financials Comparison
This section allows you to compare key financial metrics between Ouster, Inc. and BridgeBio Pharma, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
OUST vs. BBIO - Profitability Comparison
OUST - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Ouster, Inc. reported a gross profit of 20.84M and revenue of 48.58M. Therefore, the gross margin over that period was 42.9%.
BBIO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported a gross profit of 178.39M and revenue of 180.60M. Therefore, the gross margin over that period was 98.8%.
OUST - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Ouster, Inc. reported an operating income of -19.21M and revenue of 48.58M, resulting in an operating margin of -39.6%.
BBIO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported an operating income of -105.96M and revenue of 180.60M, resulting in an operating margin of -58.7%.
OUST - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Ouster, Inc. reported a net income of -17.47M and revenue of 48.58M, resulting in a net margin of -36.0%.
BBIO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported a net income of -164.04M and revenue of 180.60M, resulting in a net margin of -90.8%.
Frequently Asked Questions
OUST and BBIO have a correlation of 0.29, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
OUST has higher volatility (40.06%) compared to BBIO (12.10%). In terms of maximum drawdown, OUST dropped -98.01% vs BBIO's -92.80%.
OUST currently has the higher Sharpe Ratio (1.80 vs 1.60), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for OUST and BBIO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer